Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 2, 2010

Premium

Alan Gewirtz, professor of hematology/oncology at the University of Pennsylvania and antisense researcher, died last month.

According to the Philadelphia Inquirer, Gewirtz died of lung cancer.

He was born in New York City, and received an AB in marine biology from Colgate University in 1971 and an MD from the State University of New York at Buffalo in 1976. He joined Penn in 1990, and became a member of the school's Institute for Human Gene Therapy in 1993.

"Alan was truly a renaissance man, who while being the consummate academician always had a terrific sense of grace, life, and whimsy," Charles Abrams, professor of medicine at Penn, said in a statement announcing Gewirtz's passing. "Alan was the sort of fellow who would bring Sparky his dog to a conference, and was equally eager to debate about science or life. Alan never failed to bring smiles to our faces."


Regulus Therapeutics has appointed James Karras as its senior director of immunology.

Previously, Karras served as senior director of clinical science at Altair Therapeutics. He also spent 10 years at Isis Therapeutics, most recently as director of inflammation drug discovery, Regulus said. He holds a BA in microbiology from the University of California, San Diego, and a PhD in pharmacology and toxicology from the Medical College of Virginia.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.